Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
暂无分享,去创建一个
Kim-Anh Do | Sijin Wen | R. Millikan | K. Do | C. Logothetis | L. Pagliaro | S. Wen | Christopher J Logothetis | Randall E Millikan | Lance C Pagliaro | Melissa A Brown | Brenda Moomey | B. Moomey
[1] P. Kantoff,et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Millikan,et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] R. Paridaens,et al. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial. , 1999, Anticancer research.
[4] B. Redman,et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Thall,et al. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Lawless. Statistical Models and Methods for Lifetime Data , 2002 .
[7] A. Yagoda,et al. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.
[8] R. Priore,et al. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. , 1986, Urology.
[9] T. D. de Reijke,et al. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. , 1999, The Journal of urology.
[10] A. D'Amico,et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Troncoso,et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Itoh,et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone‐releasing hormone agonist versus flutamide plus luteinizing hormone‐releasing hormone agonist , 2004, International journal of urology : official journal of the Japanese Urological Association.
[13] P. Scardino,et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone , 1983, Cancer.
[14] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[15] R. Janknegt,et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. , 1997, Urology.
[16] K. Pummer,et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. , 1997, European urology.
[17] Jerald F. Lawless,et al. Statistical Models and Methods for Lifetime Data , 1983 .
[18] Lloyd D. Fisher,et al. Biostatistics: A Methodology for the Health Sciences , 1993 .
[19] T. Tanaka,et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. , 2001, Japanese journal of clinical oncology.
[20] R. Shah,et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. , 2008, The Journal of urology.
[21] L. Dogliotti,et al. Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases , 1998, Tumori.
[22] T. Beer,et al. Chemotherapy for hormone‐refractory prostate cancer: Beauty is in the eye of the beholder , 2000, The Prostate.
[23] C. Tangen,et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Randles,et al. Introduction to the Theory of Nonparametric Statistics , 1991 .
[25] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[26] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[27] C. Osborne,et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.